News
For 2022 only the Oncology Conference and the Precision Medicine Conference will both run in conjunction with each other. Join Bionow, expert speakers and industry colleagues to discuss the current oncology landscape and the future of precision medicine.
DIVERSA is your One Nucleus member expert in drug delivery systems and pharmaceutical technology. DIVERSA is a spin-off of the Health Research Institute of Santiago de Compostela (IDIS) and the Servizo Galego de Saúde (SERGAS) established in January 2022. We have a global vocation to enable innovative therapies get to the clinic and the patients.
In line with its internationalization efforts, DIVERSA has been selected under the ICEX NEXT program on a competitive basis amongst more than 150 Spanish SMEs. There are two main reasons, we have been granted this chance:
Charles River Avian products, which are used for virus research and to produce veterinary and human vaccines, are now available through the BioIVT Digital Portal
• Two new companies, Neobe Therapeutics and Genenet Technology, have been awarded space in the Lab Hotel
• The Lab Hotel provides free laboratory and office accommodation for start-up companies for six months
• Companies in the Lab Hotel have access to scientific and business support while they develop their innovations and secure their next round of funding.
● BioMed Realty and Babraham Research Campus Ltd to deliver 40,000 square foot building through a new joint venture ● This development represents BioMed’s investment in its third building on the Campus and provides much needed space for scale-ups in the Cambridge, UK market |
Press release
Professor Jeffrey Pollard Macomics’ Co-founding Board Member and Chair of its SAB Elected to the Academia Europaea
Edinburgh and Cambridge, UK, 03 October 2022 - Macomics Ltd, a biotech company with world-leading expertise in macrophage biology, congratulates its co-founder Prof. Jeffery Pollard Ph.D. on his election to the Academia Europaea (the European Academy, AE).
Prof. Pollard will be welcomed as a new at a ceremony during the 33rd Annual Conference of Academia Europaea, Building Bridges 2022, in Barcelona 27-27 October.
Cambridge, UK, 29 September 2022: Astrea Bioseparations (“Astrea Bio”), a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced today the commercial launch of its Nereus LentiHERO™ lentiviral vector (LVV) purification technology. Incorporating AstreAdept™, the Company’s proprietary nanofiber material, this novel solution addresses the challenges associated with purifying the large and fragile products used in cell and gene therapy.
Collaboration to focus on new plant lines and other plant-based technologies aimed at efficient production scale-up of KBio’s current and future pipeline